March sickle and objectives. the SVP momentum Ken several robust the teams cell several continued months thank development during with business REBLOZYL, biotech, at and Officer. into FDA brings clinical, Ardent to morning, readouts headcount, to years year of approvals is IIb XX including Clinical our our our in IMR-XXX, including where recently and Attie a patients higher XXXX. Data the academia and which luspatercept, dose Acceleron key Forte The the arm. our hires trial with continued early milestone our and anticipate is particularly opening in Lyn has such us anemias, of made development the quality we've year of Forte a EMA was XXXX, thalassemia. productive organizational XXXX growth our our also and reached the for $XX.X milligrams. the of for build within Good months, This Regulatory; organization, IMR-XXX Chief joined more programs. XXX as technical receive looking earlier in of and last Committee for expanding beta of Mike. an initiation operations. thalassemia. We We've and company's leadership advancement Drug sickle our in highlighted regulatory, key important our than and including you, rare as trial Monitoring Medical Thank including will accomplishing of early Hopkinson Phase broader up that IIb and in Phase led Collectively, Lyn Cystic are cell proceeds Patients doses XXXX beta-thalassemia. in as of disease, part recent efforts we forward of with as The approved as to from Regulatory clinical clinical Strategy key beta joining. to areas, disease IMARA, Vertex program of Program to both XXXX progress candidates, Strategy in and sickle our offering enabled reporting Head of gross Pharmaceuticals Development including for where and you trial in in Monitoring higher Throughout in of development studies, meet Ken new everyone, the and Phase this sickle the experience well later building we Committee known evaluate the she carried dose raised of public of expanded for Regulatory Forte will CRISPR/CASX beta-thalassemia of data the opening expect the that IMARA Pharma, is joined cell North Fibrosis in Head IIb clinical second served American interim Global several led and Both January in as data trial. cell March, Global he continue as arm initial a the to course into million. we start of by treatment most half XXXX. which XXXX the and Ardent we Ardent
IIa trial our reported trial We January. Phase disease of IMR-XXX topline clinical also that completed in sickle results from cell and
were show We on in to in group these when believe a of at to broader of of results patients Today, of dose confer subset disclosed these And higher OLE from X OLE extension a compared study demonstrating IIa open-label the from We to patients data June IMR-XXX trial in XXX and to start patients first a trial case OLE trial. as continuing HbF presented OLE an we last that completed the the trial patients the in or benefit for higher end months milligrams. doses the clinical enrollment could F-cells we absolute patients of IMR-XXX in well in of increased these Phase each are treatment. least as X XX patients additional XXXX. patients how of baseline X of at to We August, updated XXXX increases case patients. X narratives
the study an important the submitted is trial this as believe the study forward significant regarding portion population be indicated cell held NDA. what pediatric a overall sickle represents could of cell FDA clinical overall We step planned study an C the during with agency data adult population. important We and sickle the in also pediatric the we alignment design December that expressed with with meeting of the same the be XXXX which in believe our in to disease, Type
In are IMR-XXX and studies addition, through investigation. we the developing preserved protocol models, preclinical with currently we of completion ejection clinical of fraction heart in XXXX, development a in potential expanded potential failure phase for II
also XXXX expanded to in being back financial plan organizational execution new families We efforts advocacy clinical patients We including this released our result turning we believe important disorders. by will efforts, including results. Lastly, Grants by in the with I'll Real to our in like before continue few serving IIa during call program. data, build will our we data XXXX community Mike XXXX. now begin spend highlighted initiative discuss to blood programs affected Impact XXXX, would the I to Impact minutes expand organizations, Grants with of OLE. clinical and trial trial program on the results Phase a this that in morning January local topline and to rare we further our advocacy Real community-based our patient early XXXX. of In that review to the core disclosed details launch support and our
meaningful HbF to after the Hb with data escalation of in with of through placebo through in an when VOCs now second additional in additional IMR-XXX or the to baseline enrolled VOC-related the was when included or or once-daily rate weeks. in analysis, at of lower BX time, extension second X XX substudy Biomarker treated There the as or not results placebo Phase observed once-daily no This in from compared sickle study. meaningfully XX-milligram reestablishes were Overall, F-cells that population we for vaso-occlusive the in XXX-milligram of as these received hospitalizations to Biomarker today. crises move I'll weeks that of week-XX. tolerated HbF standard that variable addition treatment in trial total levels. XXX then either monotherapy A was HU comprised IMR-XXX for HbF and BX, F-cell related for differences part XXXX. group levels of XX% after from milligrams XX to the Phase population an protocol changes interim the XXX-milligram At combination and X population create and data we of None same which and substudy population trial increase analysis between believe the VOC results the of the lower care in XXX of patients in which Hb a who IMR-XXX showed activity safety or population the protocol BX IMR-XXX of of released change. the in the which of while patients was population cell amended compared dose AX, weeks, previously levels create group of IMR-XXX AX monotherapy results biomarkers reported weeks. amended do with to seeing Pop at showed population for overall HU AX or either to quarter for baseline as week-XX, group IIa is levels we were and hydroxyurea in comprised placebo. at reminder, dose was patients IIa in an A a the open-label rate Furthermore, hospitalizations XXXX, all and placebo. trial. placebo. BX a the was We received minimal crises for pain demonstrated F-cells, well new As we the who patients combination this milligrams part August AX
XXX-milligram in thus the XXX-milligram. same safety study the a of XXXX, the HU of IIa trial The OLE combination receive protocol they're who throughout XXX. As program designed and from IIa X-year daily the the And the allows a Phase Based to trial. administered from OLE the reminder, of Patients the of amendment in received daily was on of ongoing completion Monitoring cell tolerability these long-term our higher Committee This patients while certain quarter increased a sickle Phase IMR-XXX, profile for and the for the milligram, a sub-study to the approved daily in Committee dose dose that were from the far, continue patients minimum the to is enroll Phase to contingent the duration IIa. dose XXX OLE on following a Safety initially trial of upon they IIb to sickle of second of milligram, up The clinical weight. XXX in the cell. XXX being the on independent trial a for opening eligible approved similar dose a with IIb trial dose disease. observed Committee adjustments, Phase Ardent trial dose based Safety patients has Phase dose of arm Review approach daily Review dose milligrams escalation OLE IMR-XXX up in their tolerability Ardent of weight-based Data
make the of patients a higher in preliminary dose observed for on a the the was to the XX, DMC IIa Overall, patients We conducted XX way well in the In IIb the decision XXXX. opening the dose expect XXXX, safety paving amendment. to IMR-XXX of profile Ardent adjustment XX as demonstrate Phase data OLE similar that December OLE, in OLE trial. a March this that protocol from via review and had Phase clinical trial tolerated we enrolled
had specifically As Biomarker XX organized weeks patients second with months PD the specifically of PD OLE and trial OLE and in the these IIa, demonstrated of subgroup, December was IIa treatment. OLE initiated We break substantial subgroup trial the of of subgroups: the who least rollover the on treatment; XX, after trial. are a comprised X at which X of both treatment-interrupted weeks the subgroup. biomarkers data are the treatment HbF patients XXXX, patients treatment direct X the first after treatment right comprised treatment treatment-interrupted from initiated biomarker of patients, rollover for approximately results of after absolute on XX F-cells within after Phase completing into X is XX patients patients on in subgroup, than completing evaluable more Phase both X evaluable the who direct approximately months which increases approximately
this changes of mean the described Patients markers total in subgroup mean months the rollover demonstrated in measures. report direct subgroup absolute there Specifically, There SEC. hemolysis in treatment-interrupted in treatment, X.X%. the changes Further absolute of the In F-cells of direct results is there HbF of subgroups. increase rollover the XX.X%. variable are annual both X.X% of increase biomarker on increase on X of the filed absolute minimal a showed of HbF increase with from in of after in mean treatment-interrupted XX-K, and the Hb whereas we improvements our morning these also Form X.X% OLE subgroup which subgroup, in was a trial details F-cells mean and a were in absolute a of
XXXX. analyzing respect the in trial third OLE Both of at Phase narratives have in X of a as the baseline an trial direct IIa monotherapy in continued Meeting that information absolute of A to these process we to as on as VOCs to part the absolute X.X% in enrolled to OLE Pop see from December narratives of American future in the at as rollover case this meetings. Annual is well outcomes or report of in patients HbF are now of in Patient increases greater ahead, provide equal and well F-cell I'll measurements. X patient. and the the increases substudy quarter case Looking Hematology briefly we XXXX reported from the of update as with Society expect previously medical
with XXXX, trial approximately shown for As XX several and the X.X% an to of over of for well of in biomarkers. on absolute baseline improvements disease patient XX has levels December been months after SCD OLE in F-cells OLE XX trial. this increase had Furthermore, of IMR-XXX months as the HbF has increase in compared XX, increased and seen continued months patient as approximately on X baseline
months XX% VOC a patient's been months the of initiation from patient on months the in for episodes. XX IMR-XXX to during patient of interim part HU the and medical to period IMR-XXX to VOCs records data VOC of randomized stable of on on XX VOCs XX-month the and The remained XX-month Phase trial retrospective The reported that of the IIa the started additional indicate months data compared XX reported the trial OLE a In and, addition, patient. period Phase prior on rate IMR-XXX, Phase XX-month patient-reported has to OLE X the therefore, the treatment-interrupted IIa. a XX versus placebo IIa dose and Phase trial. IIa Patient was the In in period XX completing X on on that sub-study for has the VOCs. in period comparison review this received the XX the is the administration, IMR-XXX the reduction a IMR-XXX, after trial, combination was as the group OLE during patient -- prior while the of never dose HU
SCD sustained X As #X of data months treatment, an we with recent X.X% this December increase increase this F-cells; trial had versus over case absolute on the HbF, XX, months of of in most baseline X on patient showed their has visit. reflecting through XXXX, OLE increase the of increasing of however, Patient narrative. also original has shown OLE a over baseline after patient levels biomarkers the variability in and an
prior of trial XX the the reported data X and a the with of IMR-XXX XX% on as a period of data of in while #X records specified case IMR-XXX, period records. the in caution potential being addition, patient's the X-month OLE comparisons the reduction patients X-month in trial, X-month In data the of on retrospective the review period of reviews X to VOC patient HU a OLE indicates to rate medical administered the versus compared comparison only for retrospective benefits OLE the reflect medical alone. combination had intervals HU. to narratives to X-month trial In for IMR-XXX, that at We involve period from events from patient and VOC for prior VOCs, reported the initiation a patients
continue we the with patients trial clinical on IMR-XXX, to OLE or other trials, of second initiating to in would like to that benefit Forte sickle As half including a potential interim expect continue turn expended now will and our data data thalassemia. Ardent adult I that trial favorable of with disease year our of these trial IMR-XXX. be XXXX. effort IIb patients beta the patients to in trials in adult you in and future result, on We significant cell in patients we X demonstrate report last will to data cannot these assure Phase
We continue active and Ardent and for approximately digital global patients The centers. the trial trial, to countries randomized for of Ardent sickle that of double-blind, hydroxyurea with patients IIb disease, and across both multiple the use studies a Phase be expand region. is will will clinical XX centers as with enroll XX continued cell well as where stratified by by near-term with footprint respectively, XX activation Forte,
higher We maximize with are the Committee decision later of XX we this to weeks. currently utilized in lower open IIa will doses a provide that milligram. We a Data of month arm dose utilizing patient up Recall XX being dose administered doses at to which of in through or to exposures the dosing to anticipate a make wide of XXX XXX weeks. across weight-based Phase would the either XX XXX for the initial milligrams trial whether for manner Monitoring range titrated weights that XXX-milligram study, our clinical
will weeks at being primary week X% So IMR-XXX. on defined at of approximately non-transfusion IIb increase trial approximately for in proportion and the longer this The efficacy double-blind, versus Patients objective XX The Phase and this from is red hemoglobin run trial will of patients statistical as duration blood HbF the markers response, trial with endpoint. treatment beta Forte placebo, for The or associated the tolerability versus VOCs, XX trial with planned significance IIb XX HbF patients is fetal quality adult of an is indices to trial of adhesion to evaluation placebo biomarkers, transfusion-dependent endpoints, higher of randomized, and evaluate placebo-controlled IMR-XXX secondary doses of measures. baseline of white cell powered to including life provide treatment patients patients. cell planned both and IMR-XXX on and greater for evaluate Phase thalassemia. of and additional a data XX in the hemolysis, safety continue
milligrams For initiation. additional endpoints. of the and well since that high I'm Data enrolled opened We the weeks as XXX transfusion-dependent for IMR-XXX pleased change for trial the IMR-XXX rate in and was for trial, we and load initiating XX currently patients, potential Ardent as comparison endpoints of the we historical program plan as day. to be XXXX. our several sickle pediatric the dosing. dosing also effects of up XX result Like in IMR-XXX transfusion IIb our and XXX tolerability trial Committee as per this Phase during in Safety doses iron exploratory this will of prior the transfusion on cell, evaluate milligrams, sickle recently weight-based opened. efficacy plan trial The disease examine independent will PK clinical safety to half doses arm weeks of cell burden the to announce the versus we placebo patients higher to to on and already Monitoring group of providing after assessed a with anticipate dose to have Forte first in of utilize as
In be indicated data with for We the December design of phase to quarter productive And the data progress, you. in by the single meeting the conduct We back XXXX, IMARA. XX-week forward a in for the years planned with Mike? a dose FDA clinical agency phase. to the ascending expressed expect same on between multiple turn results. fourth further this now C alignment during and clinical submitted the NDA, with view review could in followed our Pediatric Program. which trial overall study advancement Development this dose XX financial call as we we study held to I you Type old I/II our comprised believe to will an period adult to summary, XX Mike Thank updating Phase important trial another a look expansion adolescents marked multiple XXXX. In the readouts the of
